Health Moderna and Merck Announce Positive Phase 3 Results for mRNA Melanoma Vaccine
Tested on patients with resected advanced melanoma, the combination therapy significantly improved recurrence-free survival compared to Keytruda alone, marking a major clinical milestone for individualized mRNA technology in oncology. Targeting High-Risk Melanoma With Bespoke…